DE122006000036I1 - Humanized immunoglobulins, their preparation and use - Google Patents

Humanized immunoglobulins, their preparation and use

Info

Publication number
DE122006000036I1
DE122006000036I1 DE1989625536 DE68925536C DE122006000036I1 DE 122006000036 I1 DE122006000036 I1 DE 122006000036I1 DE 1989625536 DE1989625536 DE 1989625536 DE 68925536 C DE68925536 C DE 68925536C DE 122006000036 I1 DE122006000036 I1 DE 122006000036I1
Authority
DE
Germany
Prior art keywords
human
cdr
receptor
tac
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1989625536
Other languages
German (de)
Other versions
DE68925536T4 (en
DE68925536T3 (en
DE68925536D1 (en
DE68925536T2 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
PDL Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26966505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122006000036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PDL Biopharma Inc filed Critical PDL Biopharma Inc
Publication of DE122006000036I1 publication Critical patent/DE122006000036I1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Compsn. comprises a pure human-like immunoglobulin (Ig) which (a) reacts specifically with p55 Tac protein and/or (b) inhibits binding of human interleukin-2 (IL-2) to its receptor. Also new are (1) human-like Ig having 2 pairs of light/heavy chains and able to react specifically with an epitope of a human IL-2 receptor with affinity at least 10 power 8 per mole, the chains including complementarily determg. regions (CDR's) and human-like framework regions (FR's), the CDR's being from different Ig molecules than FR's; (2) humanised Ig (hIg) which can bind to IL-2 receptors and contain at least one CDR from anti-Tac antibody in a human-like FR contg. at least one amino acid from the anti-Tac antibody; (3) nucleic acid encoding for human-like FR and at least one murine CDR, and (4) cells transfected with nucleic acid.
DE1989625536 1988-12-28 1989-12-28 Humanized immunoglobulins, their preparation and use Pending DE122006000036I1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29097588A 1988-12-28 1988-12-28
US31025289A 1989-02-13 1989-02-13
PCT/US1989/005857 WO1990007861A1 (en) 1988-12-28 1989-12-28 CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR

Publications (1)

Publication Number Publication Date
DE122006000036I1 true DE122006000036I1 (en) 2007-04-19

Family

ID=26966505

Family Applications (14)

Application Number Title Priority Date Filing Date
DE68925536T Expired - Lifetime DE68925536T3 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE68925536A Expired - Lifetime DE68925536D1 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINE, THEIR PRODUCTION AND USE
DE2000175038 Active DE10075038I2 (en) 1988-12-28 1989-12-28 Humanized immunoglobulins, their production and use.
DE98204240.0T Pending DE98204240T1 (en) 1988-12-28 1989-12-28 Process for the preparation of humanized immunoglobulins
DE122009000071C Pending DE122009000071I1 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE2000175005 Active DE10075005I2 (en) 1988-12-28 1989-12-28 Humanized immunoglobulins their production and use.
DE122005000057C Active DE122005000057I2 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE19975047C Active DE19975047I2 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE122005000007C Active DE122005000007I2 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE04076439.1T Pending DE04076439T1 (en) 1988-12-28 1989-12-28 Process for the preparation of humanized immunoglobulins
DE200712000037 Pending DE122007000037I1 (en) 1988-12-28 1989-12-28 Humanized immunoglobulins, their preparation and use
DE04076438.3T Pending DE04076438T1 (en) 1988-12-28 1989-12-28 Preparation of humanized immunoglobulins
DE1989625536 Pending DE122006000036I1 (en) 1988-12-28 1989-12-28 Humanized immunoglobulins, their preparation and use
DE68929061T Expired - Lifetime DE68929061T2 (en) 1988-12-28 1989-12-28 Production of human-like immunoglobulins and corresponding polynucleotides

Family Applications Before (12)

Application Number Title Priority Date Filing Date
DE68925536T Expired - Lifetime DE68925536T3 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE68925536A Expired - Lifetime DE68925536D1 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINE, THEIR PRODUCTION AND USE
DE2000175038 Active DE10075038I2 (en) 1988-12-28 1989-12-28 Humanized immunoglobulins, their production and use.
DE98204240.0T Pending DE98204240T1 (en) 1988-12-28 1989-12-28 Process for the preparation of humanized immunoglobulins
DE122009000071C Pending DE122009000071I1 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE2000175005 Active DE10075005I2 (en) 1988-12-28 1989-12-28 Humanized immunoglobulins their production and use.
DE122005000057C Active DE122005000057I2 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE19975047C Active DE19975047I2 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE122005000007C Active DE122005000007I2 (en) 1988-12-28 1989-12-28 HUMANIZED IMMUNOGLOBULINES, THEIR MANUFACTURE AND USE
DE04076439.1T Pending DE04076439T1 (en) 1988-12-28 1989-12-28 Process for the preparation of humanized immunoglobulins
DE200712000037 Pending DE122007000037I1 (en) 1988-12-28 1989-12-28 Humanized immunoglobulins, their preparation and use
DE04076438.3T Pending DE04076438T1 (en) 1988-12-28 1989-12-28 Preparation of humanized immunoglobulins

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE68929061T Expired - Lifetime DE68929061T2 (en) 1988-12-28 1989-12-28 Production of human-like immunoglobulins and corresponding polynucleotides

Country Status (32)

Country Link
EP (6) EP0682040B1 (en)
JP (6) JP2828340B2 (en)
KR (1) KR0178385B1 (en)
CN (1) CN1057013C (en)
AT (2) ATE133452T1 (en)
AU (1) AU647383B2 (en)
BG (1) BG61095B2 (en)
CA (2) CA2328851C (en)
CZ (1) CZ418691A3 (en)
DD (1) DD296964A5 (en)
DE (14) DE68925536T3 (en)
DK (2) DK119191D0 (en)
ES (5) ES2440825T3 (en)
FI (1) FI108797B (en)
FR (1) FR14C0070I1 (en)
HK (1) HK1014718A1 (en)
HR (1) HRP920500B1 (en)
HU (1) HU211174A9 (en)
IE (1) IE20000331A1 (en)
IL (2) IL162181A (en)
LU (8) LU90411I2 (en)
MC (1) MC2146A1 (en)
NL (8) NL990020I2 (en)
NO (9) NO310473B1 (en)
NZ (2) NZ314793A (en)
PT (1) PT92758B (en)
RU (1) RU2126046C1 (en)
SG (1) SG78258A1 (en)
SI (1) SI8912489B (en)
WO (1) WO1990007861A1 (en)
YU (1) YU48700B (en)
ZA (1) ZA899956B (en)

Families Citing this family (962)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
DE3900534A1 (en) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh DIAGNOSTIC PROOF USING CHIMAIR ANTIBODIES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GR1001050B (en) * 1990-01-09 1993-04-28 Protein Design Labs Inc Particular human immunoglobulin receiver of il-2 new type
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
ATE247168T1 (en) * 1991-03-06 2003-08-15 Merck Patent Gmbh HUMANIZED MONOCLONAL ANTIBODIES
NZ241855A (en) * 1991-03-07 1994-04-27 Gen Hospital Corp Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
ES2118820T3 (en) * 1991-04-05 1998-10-01 Univ Washington MONOCLONAL ANTIBODIES FOR RECEPTORS OF PLURIPOTENT CELL FACTORS.
RU2139351C1 (en) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся H- and l-chains of monoclonal antibody pm-1 (monat) to human il-6r receptor and their v-region, modified monat, its h- and l-chains and their v-regions, cdr-sequence, dna-sequence
DE69233482T2 (en) * 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69233254T2 (en) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
GB9115010D0 (en) * 1991-07-11 1991-08-28 Wellcome Found Antibody
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
MX9204374A (en) * 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
IE922436A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Induction of cytotoxic t-lymphocyte responses
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
ES2145004T3 (en) * 1991-08-21 2000-07-01 Novartis Ag DERIVATIVES OF ANTIBODIES.
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
JP3024311B2 (en) * 1991-10-03 2000-03-21 味の素株式会社 Polypeptides that bind IL-2 receptor heavy chain
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
JPH05244982A (en) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
DE69233204T2 (en) * 1991-12-13 2004-07-15 Xoma Corp., Berkeley METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
EP1997894B1 (en) * 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
GB9203459D0 (en) * 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE669986T1 (en) * 1992-11-13 1996-10-10 Idec Pharma Corp COMPLETELY FUNCTIONAL CONSENSUS-KOZAK SEQUENCES FOR MAMMAL EXPRESSION.
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
DE122004000036I1 (en) * 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutic use of chimeric and labeled antibodies to human B lymphocyte limited differentiation antigen for the treatment of B-cell lymphoma.
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
EP0804235A4 (en) * 1993-05-04 2001-09-19 Aeres Biomedical Ltd Antibodies to p-selectin and their uses
EP0751962B1 (en) 1993-05-28 2006-08-02 The Scripps Research Institute Methods for inhibiting cd14 mediated cell activation
WO1994028159A1 (en) * 1993-05-31 1994-12-08 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
ATE286510T1 (en) * 1993-09-07 2005-01-15 Smithkline Beecham Corp RECOMBINANT IL4 ANTIBODIES USEFUL IN THE TREATMENT OF IL4 CAUSED DISEASES
EP0729976A1 (en) 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
AU2185195A (en) * 1993-11-30 1995-06-19 Protein Design Labs, Inc. Reperfusion therapy using antibodies to L-selectin
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
JP4115517B2 (en) * 1994-01-25 2008-07-09 エラン ファーマシューティカルズ， インコーポレイテッド Humanized antibody against leukocyte adhesion molecule VLA-4
CA2186455A1 (en) 1994-03-29 1995-10-05 Raymond John Owens Antibodies against e-selectin
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
DE4425115A1 (en) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Method for modifying the stability of antibodies
EP0696455A1 (en) * 1994-08-11 1996-02-14 Cellena (Cell Engineering) A.G. Transferrin compositions to alleviate the side effects of cytotoxic drugs
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5707621A (en) * 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
WO1996040249A1 (en) * 1995-06-07 1996-12-19 Sloan-Kettering Institute For Cancer Research Therapeutic uses of ta99
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
GB9600660D0 (en) 1996-01-12 1996-03-13 Ciba Geigy Ag Protein
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6713305B1 (en) 1996-04-29 2004-03-30 Novartis Ag Metastasis-associated antigen and antibodies thereto
EP1378525A3 (en) 1996-06-07 2004-01-14 Neorx Corporation Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
US6833255B1 (en) 1996-07-24 2004-12-21 Novartis, Ag Drosophila melanogaster p70 S6 kinase
US6534311B2 (en) 1996-07-24 2003-03-18 Novartis Ag Drosophila melanogaster p70S6 kinase
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU725329B2 (en) * 1996-09-02 2000-10-12 Ko Okumura Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
CA2266332C (en) * 1996-09-26 2012-01-03 Chugai Seiyaku Kabushiki Kaisha Antibodies against human parathyroid hormone related protein
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US20020160005A1 (en) 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
AU713471C (en) 1996-12-23 2002-04-18 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
ZA982371B (en) * 1997-03-21 1998-09-28 Sankyo Co Humanized anti-human fas antibody
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2285769T3 (en) 1997-05-15 2007-11-16 Chugai Seiyaku Kabushiki Kaisha REMEDY FOR CAQUEXY.
CA2290485C (en) * 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
DK1019082T4 (en) 1997-10-02 2008-10-27 Max Planck Gesellschaft Method for modulating neovascularization and / or growth of collateral arteries and / or other arteries from pre-existing arteriolar connections
ATE373712T1 (en) * 1997-10-03 2007-10-15 Chugai Pharmaceutical Co Ltd NATURAL HUMAN ANTIBODIES
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
DK1069185T3 (en) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humanized antibody to human tissue factor (TF) and method of constructing humanized antibody
NZ528199A (en) 1998-08-11 2005-06-24 Idec Pharma Corp Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
JP4689781B2 (en) * 1998-09-03 2011-05-25 独立行政法人科学技術振興機構 Amino acid transport protein and its gene
CZ302997B6 (en) 1998-09-14 2012-02-15 Board Of Regents, The University Of Texas System Use of antibody or antigen-binding fragment thereof for preparing pharmaceutical composition
ES2237159T3 (en) 1998-10-06 2005-07-16 Mark Aaron Emalfarb TRANSFORMATION SYSTEM IN THE FIELD OF FILAMENT MICOTIC FUNGI IN CHRYSOSPORIUM.
DE69839740D1 (en) 1998-10-22 2008-08-28 Univ Montana Vaccine containing Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis
AU761844C (en) 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
WO2000051628A2 (en) 1999-03-03 2000-09-08 Biogen, Inc. Methods of modulating lipid metabolism and storage
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi
MXPA01010612A (en) 1999-04-22 2003-09-04 Biogen Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit.
IT1306704B1 (en) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DK1488806T3 (en) 1999-06-01 2016-02-08 Biogen Ma Inc Blocking monoclonal antibody to VLA-1 and its use in the treatment of vascular disorders
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1238985B1 (en) * 1999-09-30 2008-03-05 Kyowa Hakko Kogyo Co., Ltd. Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
ES2415708T3 (en) 1999-12-16 2013-07-26 Biogen Idec Ma Inc. Methods of treatment of ischemic or hemorrhagic lesion of the central nervous system through the use of anti-integrin alpha4 antagonists
AU2001240020B9 (en) 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
DK1265928T3 (en) 2000-01-27 2010-11-15 Medimmune Llc RSV neutralizing antibodies with ultra high affinity
MXPA02007449A (en) * 2000-02-03 2003-04-14 Millennium Pharm Inc Humanized anti ccr2 antibodies and methods of use therefor.
CA2897626C (en) 2000-02-11 2020-03-24 Biogen Idec Ma Inc. Heterologous polypeptide of the tnf family
SI1481992T1 (en) 2000-02-24 2017-01-31 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP1283057B2 (en) 2000-04-28 2012-05-30 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
CA2407715C (en) 2000-04-29 2009-03-24 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ATE327004T1 (en) 2000-10-02 2006-06-15 Chiron Corp METHOD FOR THE THERAPY OF B-CELL MALIGNITIES USING ANTAGONISTIC ANTIBODIES AGAINST CD40
WO2005019269A2 (en) 2002-11-27 2005-03-03 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
KR100975042B1 (en) 2001-04-06 2010-08-11 더 유니버시티 오브 브리스톨 Use of CD25 Binding Molecules in Steroid-Resistant Patients
JP4303475B2 (en) 2001-04-13 2009-07-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Antibody against VLA-1
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
JP2005504517A (en) * 2001-05-18 2005-02-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング CD44v6 specific antibody
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
WO2002102854A2 (en) 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
JP4675512B2 (en) * 2001-07-10 2011-04-27 三井化学株式会社 Thermal sterilization method
JP2005522192A (en) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド Multimeric proteins and methods of making and using multimeric proteins
EP1420032B2 (en) † 2001-08-03 2015-12-16 Medical & Biological Laboratories Co., Ltd. Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
EP1944040B1 (en) 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
JP4266825B2 (en) 2001-09-20 2009-05-20 イミユネツクス・コーポレイシヨン Selection of cells expressing heteromeric polypeptides
JPWO2003027151A1 (en) 2001-09-25 2005-01-06 株式会社 免疫生物研究所 Recombinant anti-osteopontin antibody and uses thereof
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
RU2004117915A (en) * 2001-11-12 2005-05-10 Мерк Патент ГмбХ (DE) MODIFIED ANTI-TNF ALPHA ANTIBODY
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP2301582B1 (en) 2001-11-21 2017-07-12 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2468733C (en) 2001-11-30 2013-06-11 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
DK1461428T3 (en) 2001-12-03 2012-06-04 Alexion Pharma Inc Method for Preparing Hybrid Antibodies
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
CN100522999C (en) * 2002-02-14 2009-08-05 免疫医疗公司 Anti-CD20 antibodies and fusion proteins thereof and methods of use
AU2003217674C1 (en) 2002-02-22 2009-03-26 Abbvie Biotherapeutics Inc. Anti-CCR5 antibody
SI1485127T1 (en) 2002-02-25 2011-09-30 Elan Pharm Inc Administration of agents for the treatment of inflammation
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CN1646160A (en) 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 Anti-alpha V beta 6 antibodies
DK1495056T3 (en) 2002-03-20 2011-05-02 Ucb Pharma Sa Method for analyzing antibody disulfide isomers
JP4432031B2 (en) 2002-03-22 2010-03-17 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． Monoclonal antibody against interleukin 13 receptor α1 (IL-13Rα1)
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP2243837A1 (en) 2002-05-14 2010-10-27 Martek Biosciences Corporation Carotene synthase gene and uses therefor
ES2370710T3 (en) 2002-05-28 2011-12-22 Ucb Pharma, S.A. PEG POSITIONAL ISOMER OF AN ANTI-TNFALFA ANTIBODY (CDP870).
DE60334453D1 (en) * 2002-05-30 2010-11-18 Macrogenics Inc CD16A BINDING PROTEINS AND USE FOR THE TREATMENT OF IMMUNE DISEASES
DE60230071D1 (en) 2002-06-14 2009-01-08 Monier Tadros METHOD FOR THE PRODUCTION OF PROTAMINE
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
GB0213745D0 (en) 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2002368055B2 (en) * 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
WO2010011999A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
BRPI0316779B8 (en) 2002-12-16 2023-02-28 Genentech Inc HUMAN ANTI-CD20 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, ITS USES, COMPOSITION, MANUFACTURED ARTICLE AND LIQUID FORMULATION
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2004066932A2 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
WO2004093908A2 (en) 2003-04-23 2004-11-04 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
CA2523142A1 (en) 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
CA2526900C (en) 2003-05-19 2015-11-24 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
EP2277908A3 (en) 2003-07-08 2011-12-14 Genentech, Inc. IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
TW201319088A (en) 2003-07-18 2013-05-16 Amgen Inc Specific binding agents to hepatocyte growth factor
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
JP4637749B2 (en) * 2003-11-11 2011-02-23 中外製薬株式会社 Humanized anti-CD47 antibody
AU2004290059A1 (en) 2003-11-12 2005-05-26 Albert Einstein College Of Medicine Of Yeshiva University Novel sequences encoding hepatitis C virus glycoproteins
JP4898452B2 (en) 2003-12-05 2012-03-14 マルチミューン ジーエムビーエイチ Anti-Hsp70 antibody for treatment and diagnosis
AU2004297265A1 (en) 2003-12-08 2005-06-23 Eisai, Inc. Antibodies that specifically bind PMS2
WO2005058244A2 (en) 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
ITRM20030601A1 (en) * 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
EP2311873B1 (en) 2004-01-07 2018-08-29 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
EP1712566A4 (en) 2004-01-19 2007-09-12 Medical & Biol Lab Co Ltd Inflammatory cytokine inhibitor
WO2005081783A2 (en) 2004-01-30 2005-09-09 Dana Farber Cancer Institute Method for determination and quantification of radiation or genotoxin exposure
WO2005077417A1 (en) 2004-02-10 2005-08-25 The Regents Of The University Of Colorado Inhibition of factor b, the alternative complement pathway and methods related thereto
EP1716179A2 (en) 2004-02-12 2006-11-02 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
CN101072797B (en) 2004-03-12 2012-05-09 瓦斯基因治疗公司 Antibody binding EPHB4, inhibiting angiogenesis and tumor growth
US20050260679A1 (en) 2004-03-19 2005-11-24 Sirid-Aimee Kellerman Reducing the risk of human anti-human antibodies through V gene manipulation
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
JP5223072B2 (en) 2004-04-02 2013-06-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and compositions for treating and preventing diseases associated with avβ5 integrin
WO2005116657A2 (en) 2004-05-24 2005-12-08 Universität Zu Köln Identification of ergothioneine transporter and therapeutic uses thereof
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
WO2006002177A2 (en) 2004-06-21 2006-01-05 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
MX2007001679A (en) 2004-08-09 2007-05-23 Elan Pharm Inc Prevention and treatment of synucleinopathic and amyloidogenic disease.
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
FI20041204A0 (en) 2004-09-16 2004-09-16 Riikka Lund Methods for the utilization of new target genes associated with immune-mediated diseases
EP1805222B1 (en) 2004-10-01 2011-02-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antibodies directed to the mammalian eag1 ion channel protein
MX2007004176A (en) 2004-10-06 2007-06-15 Mayo Foundation B7-h1 and methods of diagnosis, prognosis, and treatment of cancer.
MX2007004437A (en) 2004-10-22 2007-06-20 Amgen Inc Methods for refolding of recombinant antibodies.
JP5173426B2 (en) 2004-10-25 2013-04-03 メルク・シャープ・エンド・ドーム・コーポレイション Anti-ADDL antibodies and uses thereof
US20090202527A1 (en) 2004-11-19 2009-08-13 Biogen Idec Ma Inc. Treatment for multiple sclerosis
PE20061329A1 (en) 2004-12-15 2006-12-08 Neuralab Ltd HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
DK1772465T3 (en) 2005-01-05 2009-05-25 F Star Biotech Forsch & Entw Synthetic immunoglobulin domains with modified binding properties in regions of the molecule that are not complementarity determining regions
EP2433647A3 (en) 2005-01-27 2012-06-06 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
CN103920142A (en) 2005-02-14 2014-07-16 爱荷华大学研究基金会 Methods And Reagents For Treatment Of Age-related Macular Degeneration
EP2332408B1 (en) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Treating neurological disorders
US8048992B2 (en) 2005-02-28 2011-11-01 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
WO2006094134A2 (en) 2005-03-02 2006-09-08 Biogen Idec Ma Inc. Kim-1 antibodies for treatment of th2-mediated conditions
WO2006099141A2 (en) 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
DK1866339T3 (en) 2005-03-25 2013-09-02 Gitr Inc GTR-binding molecules and their applications
EP1875244B1 (en) 2005-03-30 2019-01-23 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
CN102989012B (en) 2005-03-31 2015-05-13 通用医疗公司 Monitoring and modulating hgf/hgfr activity
RS61229B1 (en) 2005-04-04 2021-01-29 Biogen Ma Inc Methods for evaluating an immune response to a therapeutic agent
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
CA2607455A1 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
WO2006117910A1 (en) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Monoclonal antibody against platelet membrane glycoprotein vi
WO2006117782A2 (en) 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
NZ562919A (en) 2005-05-10 2011-04-29 Incyte Corp 1,2,5-Oxadiazole-3-carboximidamide derivatives for the treatment of cancer
EP1885393A4 (en) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak Methods and compositions for immunizing against chlamydia infection
US8858935B2 (en) 2005-05-19 2014-10-14 Amgen Inc. Compositions and methods for increasing the stability of antibodies
JP5707024B2 (en) 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Agents that inhibit the complement alternative pathway to treat traumatic brain injury, spinal cord injury and related conditions
HUE030701T2 (en) 2005-05-27 2017-05-29 Biogen Ma Inc Tweak binding antibodies
EP1899376A2 (en) 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antibodies against hmgb1 and fragments thereof
EP1907001B1 (en) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
KR101502920B1 (en) * 2005-06-21 2015-03-17 조마 (유에스) 엘엘씨 IL-1β Binding antibodies and fragments thereof
CN104072614B (en) 2005-07-08 2017-04-26 生物基因Ma公司 Anti-alpha[v]beta[6] antibodies and uses thereof
MX2008000984A (en) 2005-07-22 2008-04-04 Progenics Pharm Inc Methods for reducing viral load in hiv-1-infected patients.
FR2888850B1 (en) 2005-07-22 2013-01-11 Pf Medicament NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
EP1913027B1 (en) 2005-07-28 2015-03-04 Novartis AG M-csf specific monoclonal antibody and uses thereof
WO2007030560A2 (en) 2005-09-08 2007-03-15 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
CN101313216A (en) 2005-09-22 2008-11-26 普洛茨股份有限公司 Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2007051077A2 (en) 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
CA2627309A1 (en) 2005-10-28 2007-05-03 Meiji Seika Kaisha, Ltd. Pseudomonas aeruginosa outer membrane protein pa5158
AU2006337105B2 (en) 2005-11-01 2013-05-02 Abbvie Biotechnology Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
EP1957541A2 (en) 2005-11-21 2008-08-20 Laboratoires Serono SA Compositions and methods of producing hybrid antigen binding molecules and uses thereof
RS53270B2 (en) 2005-11-30 2018-05-31 Abbvie Deutschland Monoclonal antibodies against amyloid beta protein and uses thereof
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
ES2396440T3 (en) 2006-01-18 2013-02-21 The General Hospital Corporation Methods of increasing lymphatic function
JP2009531295A (en) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ Methods for treating autoimmune or demyelinating diseases
US20070218065A1 (en) 2006-03-10 2007-09-20 Jaspers Stephen R Antibodies that bind both il-17a and il-17f and methods of using the same
US9315578B2 (en) 2006-03-23 2016-04-19 Tohoku Univeristy High functional bispecific antibody
AU2007232894B2 (en) 2006-03-30 2013-01-31 Meiji Seika Kaisha, Ltd. Pseudomonas aeruginosa outer membrane protein PA0427
KR20150006085A (en) 2006-04-05 2015-01-15 애브비 바이오테크놀로지 리미티드 Antibody purification
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2703010A3 (en) 2006-04-10 2014-08-06 AbbVie Biotechnology Ltd Uses and compositions for treatment of rheumatoid arthritis
EP2034830B1 (en) 2006-05-25 2014-09-03 Biogen Idec MA Inc. Anti-vla-1 antibody for treating stroke
MX2008015309A (en) 2006-05-31 2009-03-02 Astellas Pharma Inc Humanized anti-human osteopontin antibody.
US8357781B2 (en) 2006-06-01 2013-01-22 Janssen Alzheimer Immunotherapy Neuroactive fragments of APP
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
CA2651992A1 (en) 2006-06-30 2008-01-10 Abbott Biotechnology Ltd. Automatic injection device
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
JP2009542196A (en) 2006-07-07 2009-12-03 インターセル アーゲー Small Streptococcus pyogenes antigens and their use
EP2046374A4 (en) 2006-07-10 2010-05-05 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
RU2009107707A (en) 2006-08-04 2010-09-10 Новартис АГ (CH) SPECIFIC TO EphB3 ANTIBODY AND ITS APPLICATION
EP2056709A4 (en) 2006-08-11 2013-05-01 Univ New Jersey Med Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof
EP3415532A1 (en) 2006-08-18 2018-12-19 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
EP2500416A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
CA2910619A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
FR2906533B1 (en) 2006-09-28 2013-02-22 Pf Medicament METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED THEREBY AND USES THEREOF
AU2007315211B2 (en) 2006-11-03 2013-01-17 U3 Pharma Gmbh FGFR4 antibodies
AU2007318483B2 (en) 2006-11-10 2013-05-02 Livtech Inc. Anti-human Dlk-1 antibody showing anti-tumor activity in vivo
MX2009005175A (en) 2006-11-17 2009-08-07 Novartis Ag Lingo binding molecules and pharmaceutical use thereof.
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US8288110B2 (en) 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
BRPI0720437A2 (en) 2006-12-07 2014-01-07 Novartis Ag ANHPHONE ANTIBODIES AGAINST EPHB3
WO2008073914A2 (en) 2006-12-10 2008-06-19 Dyadic International Inc. Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
WO2008083239A2 (en) 2006-12-27 2008-07-10 The Johns Hopkins University Compositions and methods for stimulating an immune response
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US9023984B2 (en) 2006-12-29 2015-05-05 The Regents Of The University Of Colorado, A Body Corporate Diagnostic and therapeutic target for autoimmune diseases and uses thereof
EP2426143B1 (en) 2007-01-05 2017-06-28 University of Zurich Method of providing disease-specific binding molecules and targets
EP2120984A2 (en) 2007-01-12 2009-11-25 Intercell AG Protective proteins of s. agalactiae, combinations thereof and methods of using the same
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
DK2130044T3 (en) 2007-02-16 2017-02-06 Genzyme Corp PROCEDURE FOR IDENTIFYING THE RISK OF A THYRODOIDE DISORDER
CN104189885A (en) 2007-02-23 2014-12-10 纽约哥伦比亚大学理事会 METHODS TO ACTIVATE OR BLOCK THE HLA-E/Qa-1 RESTRICTED CD8+T CELL REGULATORY PATHWAY TO TREAT IMMUNOLOGICAL DISEASE
PL2583978T3 (en) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Prevention and treatment of synucleinopathic and amyloidogenic disease
PT2118300E (en) 2007-02-23 2015-09-22 Univ California Prevention and treatment of synucleinopathic and amyloidogenic disease
MX2009009926A (en) 2007-03-13 2010-03-15 Univ Zuerich Monoclonal human tumor-specific antibody.
CN103214577B (en) 2007-03-22 2015-09-02 生物基因Ma公司 Specific binding CD154 comprises associated proteins of antibody, antibody derivatives and antibody fragment and uses thereof
DK2137217T3 (en) 2007-04-05 2014-03-17 Morphotek Inc Methods of inhibiting the binding of endosialin to ligands
EP2150564A2 (en) 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2497779A1 (en) 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
US8962273B2 (en) 2007-05-11 2015-02-24 Genzyme Corporation Methods of producing a secreted protein
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
AU2008266051B2 (en) 2007-06-14 2014-07-31 Biogen Ma Inc. Antibody formulations
EP2511291A3 (en) 2007-06-18 2012-11-07 Intercell AG Chlamydia antigens
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
WO2009001940A1 (en) 2007-06-27 2008-12-31 Asubio Pharma Co., Ltd. Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
CN101784564B (en) 2007-07-13 2014-07-02 约翰霍普金斯大学 B7-DC variants
EP2537529B1 (en) 2007-08-02 2018-10-17 Gilead Biologics, Inc. Loxl2 inhibitory antibodies and uses thereof
NZ583966A (en) 2007-08-30 2012-04-27 Daiichi Sankyo Co Ltd Anti-epha2 antibody
JPWO2009031230A1 (en) * 2007-09-06 2010-12-09 国立大学法人大阪大学 Anti-CD20 monoclonal antibody
WO2009033071A2 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
US20100239570A1 (en) 2007-09-13 2010-09-23 Roger Nitsch Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
JP5963341B2 (en) 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド Homogeneous antibody population
ES2445590T3 (en) 2007-10-05 2014-03-04 Genentech, Inc. Use of anti-beta amyloid antibody in eye diseases
ES2540733T3 (en) 2007-10-11 2015-07-13 Daiichi Sankyo Company, Limited Antibody that targets Siglec-15 osteoclast-related protein
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
SG185316A1 (en) 2007-10-19 2012-11-29 Immunas Pharma Inc ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF
WO2009059317A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
CA2704357C (en) 2007-11-02 2016-06-21 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
WO2009062112A2 (en) 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Use of tam receptor inhibitors as antimicrobials
MX2010005031A (en) 2007-11-12 2010-06-25 U3 Pharma Gmbh Axl antibodies.
MX347246B (en) 2007-11-28 2017-04-19 Univ Pennsylvania Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof.
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
EP2808345A3 (en) 2007-12-05 2015-03-11 Massachusetts Institute of Technology Aglycosylated immunoglobulin mutants
US8779088B2 (en) 2007-12-17 2014-07-15 Marfl Ab Vaccine for the treatment of Mycobacterium related disorders
EP2236515A4 (en) 2007-12-25 2012-10-31 Meiji Seika Kaisha Component protein pa1698 for type-iii secretion system of pseudomonas aeruginosa
CN102016059B (en) 2007-12-28 2014-10-22 依兰制药公司 Treatment and prophylaxis of amyloidosis
BRPI0906492A2 (en) 2008-01-11 2015-12-01 Synovex Corp cadherin-11 antagonists and methods for the treatment of inflammatory joint diseases
CA2711771C (en) 2008-01-11 2017-01-24 Gene Techno Science Co., Ltd. Humanized anti-.alpha.9 integrin antibodies and the uses thereof
KR101634636B1 (en) 2008-01-11 2016-06-29 아스텔라스세이야쿠 가부시키가이샤 - 9 improved humanized anti-human 9-integrin antibody
AU2009211635B2 (en) 2008-02-08 2014-06-26 Immunas Pharma, Inc. Antibody capable of binding specifically to Abeta-oligomer, and use thereof
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
PL2262838T3 (en) 2008-03-13 2016-10-31 Agent for treating disease
CA2717812A1 (en) 2008-03-13 2009-09-17 Biotest Ag Agent for treating disease
SG190598A1 (en) 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
WO2009115508A2 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
EP2268313A2 (en) 2008-03-17 2011-01-05 Universitätsklinikum Münster Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
US8017118B2 (en) 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo
WO2009119794A1 (en) 2008-03-27 2009-10-01 タカラバイオ株式会社 Prophylactic/therapeutic agent for infectious disease
SG189776A1 (en) 2008-04-11 2013-05-31 Seattle Genetics Inc Detection and treatment of pancreatic, ovarian and other cancers
EP2282773B1 (en) 2008-05-02 2014-01-15 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
EP3384919A1 (en) 2008-06-02 2018-10-10 Dana Farber Cancer Institute, Inc. Cs1 peptides
CN102124030B (en) 2008-06-20 2015-06-17 国立大学法人冈山大学 Antibody against oxidized ldl/ss2gpi complex and use of the same
SI3628686T1 (en) 2008-06-25 2022-01-31 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
JP5856480B2 (en) 2008-06-25 2016-02-09 エスバテック − ア ノバルティスカンパニー エルエルシー Humanization of rabbit antibodies using a versatile antibody framework
TWI453204B (en) 2008-07-08 2014-09-21 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2010008051A1 (en) 2008-07-16 2010-01-21 株式会社医学生物学研究所 Anti-human clcp1 antibody and use thereof
EP2322220B1 (en) 2008-08-01 2014-01-01 Axis, Inc. Therapeutic agent or preventive agent for osteoarthritis
US8795981B2 (en) 2008-08-08 2014-08-05 Molecular Devices, Llc Cell detection
US8417011B2 (en) 2008-09-18 2013-04-09 Molecular Devices (New Milton) Ltd. Colony detection
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
US8715654B2 (en) 2008-10-02 2014-05-06 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
KR20110069144A (en) 2008-10-09 2011-06-22 미네르바 바이오테크놀로지 코포레이션 Method for inducing pluripotency in cells
DK3199553T3 (en) 2008-10-29 2019-07-22 Circular Commitment Company METHODS AND AGENTS FOR DIAGNOSTICATION AND TREATMENT OF HEPATOCELLULAR CARCINOM
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DK2350269T3 (en) 2008-10-31 2015-12-07 Univ Pennsylvania ABE ADENOVIRUS WITH SADV-46 HEXONCAPSIDE PROTEINS AND APPLICATIONS THEREOF
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
AR074439A1 (en) 2008-12-02 2011-01-19 Pf Medicament ANTI-CMET ANTIBODY (C-MET RECEIVER)
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
US8313915B2 (en) 2009-01-21 2012-11-20 Gundersen Lutheran Medical Foundation, Inc. Early detection of canine lyme disease by specific peptides and antibodies
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
WO2010096658A1 (en) 2009-02-19 2010-08-26 The Cleveland Clinic Foundation Corin as a marker for heart failure
CN105884903B (en) 2009-03-10 2019-12-06 贝勒研究院 Antigen presenting cell targeted vaccines
EP2406286B1 (en) 2009-03-10 2016-05-18 Baylor Research Institute Anti-cd40 antibodies and uses thereof
ES2618864T3 (en) 2009-03-10 2017-06-22 Baylor Research Institute Vaccines targeting antigen presenting cells
WO2010109924A1 (en) 2009-03-25 2010-09-30 国立大学法人東北大学 Lh-type bispecific antibody
WO2010117011A1 (en) 2009-04-09 2010-10-14 第一三共株式会社 ANTI-Siglec-15 ANTIBODY
US20120121706A1 (en) 2009-04-10 2012-05-17 Tufts Medical Center, Inc. PAR-1 Activation by Metalloproteinase-1 (MMP-1)
US9090679B2 (en) 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
EP2246364A1 (en) 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
BRPI1012162A2 (en) 2009-04-29 2016-01-12 Abbott Biotech Ltd automatic injection device
EP2270053A1 (en) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
EP2435559A1 (en) 2009-05-29 2012-04-04 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
EP2260864A1 (en) 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
TWI513465B (en) 2009-06-25 2015-12-21 Regeneron Pharma Method of treating cancer with dll4 antagonist and chemotherapeutic agent
CA2767409C (en) 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
SG177763A1 (en) 2009-07-28 2012-03-29 Hoffmann La Roche Non-invasive in vivo optical imaging method
AU2010280981B2 (en) 2009-08-05 2016-01-28 Nexigen Gmbh Human HCV-interacting proteins and methods of use
WO2011024114A1 (en) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
TWI412375B (en) 2009-08-28 2013-10-21 Roche Glycart Ag Humanized anti-cdcp1 antibodies
CN102666581A (en) 2009-08-31 2012-09-12 艾普利穆恩公司 Methods and compositions for the inhibition of transplant rejection
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2308897A1 (en) 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
US9377458B2 (en) 2009-10-11 2016-06-28 Biogen Ma Inc. Anti-VLA-4 related assays
JP5818003B2 (en) 2009-11-18 2015-11-18 国立大学法人東北大学 High-functional variant of humanized anti-EGFR antibody variable region
EP2332929A1 (en) 2009-11-25 2011-06-15 ArisGen SA Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011068870A2 (en) 2009-12-01 2011-06-09 President And Fellows Of Harvard College Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
WO2011075578A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of treating interstitial cystitis
US9221759B2 (en) 2010-01-13 2015-12-29 Rutgers, The State University Of New Jersey Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
AU2011207253B2 (en) 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
CA2787755A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
JP2012246222A (en) 2010-01-29 2012-12-13 Axis Inc Use for production of therapeutic agent or prophylactic agent for osteoarthritis
CN102821786B (en) 2010-01-29 2016-01-13 阿克西斯股份有限公司 Injection containing osteoarthritis treatment agent
CN102811737A (en) 2010-01-29 2012-12-05 阿克西斯股份有限公司 Pharmaceutical composition for treatment or prevention of osteoarthritis, and method of production therefor
CA2789168A1 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
TWI504410B (en) 2010-02-08 2015-10-21 Agensys Inc Antibody drug conjugates (adc) that bind to 161p2f10b proteins
RU2565539C2 (en) 2010-02-18 2015-10-20 Те Риджентс Оф Те Юниверсити Оф Калифорния INTEGRIN ανβ8 NEUTRALISING ANTIBODIES
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
JP6190113B2 (en) * 2010-03-03 2017-08-30 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Oligomer-specific amyloid beta epitopes and antibodies
AU2011231558B2 (en) 2010-03-26 2016-08-11 Westfaelische Wilhelms-Universitaet Muenster Substitute therapy for glucocorticoids
EP2371863A1 (en) 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
BR112012025728B1 (en) 2010-04-09 2022-01-11 Critical Care Diagnostics, Inc ISOLATED ANTIBODIES OR FRAGMENTS THAT BIND TO SOLUBLE HUMAN ST2, HYBRIDOMA, KIT, AS WELL AS METHODS FOR QUANTIFICATION OF A LEVEL OF HUMAN SOLUBLE ST2 IN A SAMPLE FROM AN INDIVIDUAL, AND FOR PREDICTING THE RISK OF DEATH WITHIN ONE YEAR IN AN INDIVIDUAL
SG10201502967RA (en) 2010-04-16 2015-05-28 Biogen Ma Inc Anti-vla-4 antibodies
KR101850687B1 (en) 2010-04-21 2018-04-20 애브비 바이오테크놀로지 리미티드 Wearable automatic injection device for controlled delivery of therapeutic agents
WO2011138462A1 (en) 2010-05-07 2011-11-10 F. Hoffmann-La Roche Ag Diagnostic method for the detection of cells ex vivo
EA201500220A1 (en) 2010-05-17 2015-10-30 Ливтех, Инк. ANTIBODY AGAINST TROP-2 PERSON HAS ANTI-TUMOR ACTIVITY IN VIVO
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
WO2012005076A1 (en) 2010-07-08 2012-01-12 本田技研工業株式会社 High frequency heating coil
CA2805414C (en) 2010-07-14 2020-07-07 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
CN103153331B (en) 2010-07-15 2017-03-22 亚德赫伦医疗公司 Humanized antibodies targeting the EC1 domain of cadherin-11 and related compositions and methods
NZ605928A (en) 2010-07-29 2015-02-27 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
BR112013002297A2 (en) 2010-07-30 2016-05-24 Ac Immune Sa safe and functional humanized antibodies
JP2012034668A (en) 2010-08-12 2012-02-23 Tohoku Univ Fragment of humanized anti-egfr antibody substituted-lysine variable region, and use thereof
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
WO2012025636A1 (en) 2010-08-27 2012-03-01 University Of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
AU2011295030B2 (en) 2010-08-27 2016-01-28 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US8497138B2 (en) 2010-09-30 2013-07-30 Genetix Limited Method for cell selection
JP5843170B2 (en) 2010-09-30 2016-01-13 国立研究開発法人理化学研究所 Method for treating glioma, method for examining glioma, method for delivering desired substance to glioma, and drug used in these methods
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
UA118646C2 (en) 2010-10-13 2019-02-25 Янссен Байотек, Інк. Human oncostatin m antibodies and methods of use
EP2630160B1 (en) 2010-10-18 2016-11-09 MediaPharma S.r.l. Erbb3 binding antibody
UY33679A (en) 2010-10-22 2012-03-30 Esbatech STABLE AND SOLUBLE ANTIBODIES
EP3581206A1 (en) 2010-10-22 2019-12-18 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway
PT3326645T (en) 2010-10-25 2020-06-23 Biogen Ma Inc Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
CA2814908A1 (en) 2010-10-27 2012-05-03 Pierre Fabre Medicament Antibodies for the treatment of hiv
CN103282495B (en) 2010-10-29 2017-06-09 第一三共株式会社 New Anti-DR5 antibody
US9072766B2 (en) 2010-11-18 2015-07-07 Beth Israel Deaconess Medical Center, Inc. Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
SG10201509499RA (en) 2010-11-19 2015-12-30 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
EP3075860A1 (en) 2010-11-23 2016-10-05 The Trustees of the University of Pennsylvania Subfamily e simian adenovirus a1295 and uses thereof
JP6067575B2 (en) 2010-12-17 2017-01-25 ニューリミューン ホールディング エイジー Human anti-SOD1 antibody
WO2012090939A1 (en) 2010-12-27 2012-07-05 国立大学法人名古屋大学 Method for suppressing receptor tyrosine kinase-mediated prosurvival signaling in cancer cells
ES2617983T3 (en) 2011-01-10 2017-06-20 Ct Atlantic Ltd. Combination therapy that includes tumor-associated antigen binding antibodies
PT2663579T (en) 2011-01-14 2017-07-28 Univ California Therapeutic antibodies against ror-1 protein and methods for use of same
EP3187216B1 (en) 2011-01-24 2019-08-21 AbbVie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012110843A1 (en) 2011-02-18 2012-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
US20140044644A1 (en) 2011-02-21 2014-02-13 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
JP6385060B2 (en) 2011-03-07 2018-09-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト In vivo selection of therapeutically active antibodies
EP2683290B1 (en) 2011-03-07 2018-11-07 F.Hoffmann-La Roche Ag Methods for in vivo testing of therapeutic antibodies
US10139420B2 (en) 2011-03-09 2018-11-27 ISNERM (Institut National de la Sante et de la Recherche Medicale) Methods for treating vaso-occlusive crisis using non-modified annexin V
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
WO2012123590A1 (en) 2011-03-17 2012-09-20 Miltenyi Biotec Gmbh Cell preparations depleted of tcr alpha/beta
TW201300418A (en) 2011-03-25 2013-01-01 Baylor Res Inst Compositions and methods to immunize against hepatitis C virus
TW201249867A (en) 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
EP4299093A3 (en) 2011-04-21 2024-03-13 AbbVie Inc. Wearable automatic injection device for controlled administration of therapeutic agents
LT2703486T (en) 2011-04-25 2018-05-25 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
PE20141672A1 (en) 2011-05-02 2014-11-26 Millennium Pharm Inc FORMULATION FOR ANTI-alpha4�7 ANTIBODY
UA116189C2 (en) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. FORMULATION FOR ANTI-α4β7 ANTIBODY
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
US20140086827A1 (en) 2011-05-09 2014-03-27 The Cleveland Clinic Foundation Serum S100B And Uses Thereof
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2530088A1 (en) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Means and methods for diagnosing and treating multiple sclerosis
JP2014524891A (en) 2011-06-03 2014-09-25 シーティー アトランティック リミテッド MAGEA3 binding antibody
JP2014518889A (en) 2011-06-03 2014-08-07 シーティー アトランティック リミテッド MAGEA3 binding antibody
CA2836373A1 (en) 2011-06-06 2012-12-13 Neotope Biosciences Limited Mcam antagonists and methods of treatment
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
AU2012272790B2 (en) 2011-06-23 2016-10-06 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
DE202011103324U1 (en) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutic anti-TIRC7 antibodies for use in immune and other diseases
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
US8986952B2 (en) 2011-08-11 2015-03-24 Astellas Pharma Inc. Anti-human NGF antibody
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20140242085A1 (en) 2011-08-12 2014-08-28 Medical & Biological Laboratories Co., Ltd. Methods and composition for testing, preventing, and treating aspergillus fumigatus infection
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP3275461A1 (en) 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
GB2495115A (en) * 2011-09-29 2013-04-03 Oxford Plastic Sys Ltd Base for supporting temporary fence panels or posts.
AR088048A1 (en) 2011-10-04 2014-05-07 Univ Columbia NOTCH1 HUMAN LURE
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
US20140248294A1 (en) 2011-10-05 2014-09-04 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
EP2768971A1 (en) 2011-10-20 2014-08-27 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for the detection and the treatment of cardiac remodeling
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
US20140328864A1 (en) 2011-11-22 2014-11-06 Inserm (Institut National De La Sente Et De La Recherche Medicale) Methods and pharmaceutical compositions for reducing airway hyperresponse
WO2013079487A1 (en) 2011-11-28 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
EP2602621A1 (en) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, a novel urinary marker for transitional cell carcinoma detection
RU2658438C2 (en) * 2011-12-13 2018-06-21 Нордик Нановектор Аса Chimeric therapeutic anti-cd-37 antibody hh1
FR2984750B1 (en) 2011-12-23 2014-01-10 Lfb Biotechnologies NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING A HUMAN RECEPTOR ANTIBODY OF ANTI-MULLERIAN HORMONE TYPE II
WO2013093122A2 (en) 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
AU2013206788B2 (en) 2011-12-28 2017-11-30 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
US20150216998A1 (en) 2012-01-01 2015-08-06 Ramot At Tel-Aviv University Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
ES2725569T3 (en) 2012-02-10 2019-09-24 Seattle Genetics Inc Diagnosis and treatment of cancers that express CD30
EP2814468B1 (en) 2012-02-16 2019-06-19 Santarus, Inc. Anti-vla1 (cd49a) antibody pharmaceutical compositions
EP2817340B1 (en) 2012-02-23 2020-12-09 Daiichi Sankyo Europe GmbH Her3 inhibitor for modulating radiosensitivity
ES2701064T3 (en) 2012-02-28 2019-02-20 Astellas Pharma Inc Novel human IL-23 anti-receptor antibody
EP2825200A4 (en) 2012-03-15 2015-08-26 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
US9567392B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
KR20140138215A (en) 2012-03-30 2014-12-03 다이이찌 산쿄 가부시키가이샤 Novel anti-siglec15 antibody
IN2014DN08215A (en) 2012-03-30 2015-05-15 Daiichi Sankyo Companyltd
ES2702278T3 (en) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Extracellular matrix metalloproteinase (emmprin) inducer peptides and binding antibodies
CN103382223B (en) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 Multi-functional antibody polypeptide aiming at epidermal growth factor receptor (EGFR) cryptic epitope and T cell antigen
JP2015514985A (en) 2012-04-02 2015-05-21 ガンダーセン ルゼラン ヘルス システム，インコーポレイテッド Reagents, methods and kits for cancer classification
JP6188681B2 (en) 2012-04-09 2017-08-30 第一三共株式会社 Anti-FGFR2 antibody
IN2014DN07799A (en) 2012-04-27 2015-05-15 Daiichi Sankyo Co Ltd
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
EP2848633B1 (en) 2012-05-11 2019-02-06 Microbial Chemistry Research Foundation Anti-cxadr antibody
BR112014028306A2 (en) 2012-05-15 2018-04-17 Morphotek, Inc. methods for treating gastric cancer.
BR112014028684A2 (en) 2012-05-18 2017-07-25 Univ Pennsylvania simian subfamily and adenovirus a1302, a1320, a1331 and a1337 and uses thereof
JP2015520373A (en) 2012-05-22 2015-07-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Method for diagnosing and treating focal segmental glomerulosclerosis
SG11201408330XA (en) 2012-05-24 2015-01-29 Mountgate Group Ltd Compositions and methods related to prevention and treatment of rabies infection
PT3338794T (en) 2012-07-13 2020-04-24 Childrens Hospital Philadelphia Toxicity management for anti-tumor activity of cars
JP6293137B2 (en) 2012-07-18 2018-03-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods for preventing and treating chronic kidney disease (CKD)
AU2013290424B2 (en) 2012-07-19 2018-01-25 Redwood Bioscience, Inc. Antibody specific for CD22 and methods of use thereof
WO2014021339A1 (en) 2012-07-30 2014-02-06 国立大学法人名古屋大学 Monoclonal antibody against human midkine
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
TWI595007B (en) 2012-09-10 2017-08-11 Neotope Biosciences Ltd Anti-mcam antibodies and associated methods of use
SG11201501924UA (en) 2012-09-13 2015-05-28 Chugai Pharmaceutical Co Ltd Gene knock-in non-human animal
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
LT2905335T (en) 2012-10-03 2018-04-10 Chiome Bioscience Inc. Anti-human dlk-1 antibody having anti-tumor activity in vivo
EP3677310A1 (en) 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
CN115960111A (en) 2012-10-11 2023-04-14 第一三共株式会社 Antibody-drug conjugates
DE102012020496A1 (en) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Invitro diagnosis and/or early detection of neurofibromatosis type 1 and/or neurofibromatosis type 1-associated tumor from sample of a patient for treating the patient with the tumor, comprises detecting protein or its fragment in sample
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
WO2014064203A1 (en) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
CA2889764C (en) 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
CA2890265C (en) 2012-11-05 2023-01-17 Pierre Fabre Medicament Antigen binding proteins and their use as addressing product for the treatment of cancer
JP6445446B2 (en) 2012-11-08 2018-12-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and pharmaceutical compositions for the treatment of bone metastases
AR093445A1 (en) 2012-11-14 2015-06-10 Regeneron Pharma METHODS TO TREAT OVARY CANCER WITH DLL4 ANTAGONISTS
PT2928923T (en) 2012-12-10 2020-03-27 Biogen Ma Inc Anti-blood dendritic cell antigen 2 antibodies and uses thereof
JP6461808B2 (en) 2012-12-17 2019-01-30 ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Use of monoclonal antibodies in the treatment of inflammation and bacterial infections
WO2014100602A1 (en) 2012-12-20 2014-06-26 Hospital For Special Surgery Treatment of egf-receptor dependent pathologies
KR102234324B1 (en) 2012-12-21 2021-03-31 바이오젠 엠에이 인코포레이티드 Human anti-tau antibodies
CN104936980B (en) 2012-12-31 2019-06-07 生物控股有限公司 For treating and preventing the recombinant human antibody of the relevant disease of polyomavirus
EP2752426A1 (en) 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof
JP6247646B2 (en) 2013-01-28 2017-12-13 株式会社イーベック Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
US20150377888A1 (en) 2013-02-01 2015-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for Predicting and Preventing Metastasis in Triple Negative Breast Cancers
EP2955226B1 (en) 2013-02-08 2019-06-26 Medical & Biological Laboratories Co., Ltd. Antibodies to human nrg1 protein
CN104884470A (en) 2013-02-15 2015-09-02 艾斯巴技术-诺华有限责任公司 Acceptor framework for CDR grafting
CN104884471A (en) 2013-02-20 2015-09-02 艾斯巴技术-诺华有限责任公司 Acceptor framework for CDR grafting
FR3004184B1 (en) 2013-02-26 2016-03-18 Agronomique Inst Nat Rech ANTI-GLUTEN ANTIBODY DESAMIDE AND USES THEREOF.
EP2963059B1 (en) 2013-02-28 2018-04-04 National Cancer Center Antibody against insoluble fibrin
JP6218088B2 (en) 2013-03-08 2017-11-01 国立大学法人大阪大学 Antibody against peptide encoded by Exon-21 site of periostin and pharmaceutical composition for prevention or treatment of inflammation-related disease comprising the antibody
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
DK2968468T3 (en) 2013-03-13 2021-07-26 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
EP2968550B1 (en) 2013-03-14 2018-11-14 Ffe Therapeutics LLC Compositions and methods for treating angiogenesis-related disorders
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CN105392801A (en) 2013-03-15 2016-03-09 比奥根Ma公司 Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EA201591495A1 (en) 2013-03-18 2016-05-31 Биосерокс Продактс Б.В. HUMANIZED ANTIBODIES AGAINST CD134 (OX40) AND APPLICATIONS OF THE SPECIFIED ANTIBODIES
EP2981554B1 (en) 2013-04-01 2020-07-29 The Regents of The University of California Methods and compositions for treating and preventing disease associated with avb8 integrin
WO2014174596A1 (en) 2013-04-23 2014-10-30 株式会社医学生物学研究所 Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104140974B (en) 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 Encode the nucleic acid of the Chimeric antigen receptor albumen of GPC 3 and express the T lymphocytes of the Chimeric antigen receptor albumen of GPC 3
CA2952390A1 (en) 2013-06-20 2014-12-24 The Trustees Of The University Of Pennsylvania Methods for diagnosing pancreatic cancer
US10112995B2 (en) 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
US20160176943A1 (en) 2013-07-05 2016-06-23 Inserm (Insititut National De La Sante Et De La Recherche Medicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
JP6450381B2 (en) 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション Soluble MIC neutralizing monoclonal antibody for treating cancer
PT3031913T (en) 2013-08-09 2019-05-31 Astellas Pharma Inc Novel anti-human tslp receptor antibody
US20160216262A1 (en) 2013-09-12 2016-07-28 Institut National De La Sante Et De La Recherche Medicale Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies
AU2014322988B2 (en) 2013-09-20 2018-12-06 Westfaelische Wilhelms-Universitaet Muenster Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy
EP3049438B1 (en) 2013-09-24 2018-07-25 The Feinstein Institute for Medical Research Peptides inhibiting cold-inducible rna binding protein activity
US9974788B2 (en) 2013-09-26 2018-05-22 Beth Israel Deaconess Medical Center, Inc. Inhibition of SGK1 in the treatment of heart conditions
SG11201602490UA (en) 2013-09-30 2016-04-28 Daiichi Sankyo Co Ltd Anti-lps o11 antibody
EP3470081A1 (en) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
US9931401B2 (en) 2013-10-08 2018-04-03 Daiichi Sankyo Company, Limited Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor
JP6556742B2 (en) 2013-11-06 2019-08-07 ヤンセン バイオテツク，インコーポレーテツド Anti-CCL17 antibody
JPWO2015068781A1 (en) 2013-11-06 2017-03-09 国立大学法人大阪大学 Antibodies with broad neutralizing activity against group 1 of influenza virus type A
JP2016538286A (en) 2013-11-15 2016-12-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and pharmaceutical compositions for treating pancreatic cancer
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
CN105829534B (en) 2013-12-24 2021-08-03 安斯泰来制药株式会社 Anti-human BDCA-2 antibodies
CA2933666C (en) 2013-12-25 2021-08-03 Sapporo Medical University Anti-trop2 antibody-drug conjugate
EP4101461A1 (en) 2014-01-09 2022-12-14 Hadasit Medical Research Services and Development Ltd. Improved cell compositions and methods for cancer therapy
JP7037884B2 (en) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート New vaccines for HPV and HPV-related diseases
CN104774264B (en) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 Anti-human proBDNF monoclonal antibodies and its effect in pain
IL310627A (en) 2014-01-31 2024-04-01 Daiichi Sankyo Company Ltd Anti-her2 antibody-drug conjugates, compositions comprising same and uses thereof
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
ES2831014T3 (en) 2014-02-18 2021-06-07 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of diseases mediated by the signaling pathway of the NRP-1 / OBR complex
EP3415160B1 (en) 2014-03-04 2021-08-18 Klinikum der Universität München Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
EP3122768A2 (en) 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
SG10201907807XA (en) 2014-04-10 2019-09-27 Daiichi Sankyo Co Ltd Anti-her3 antibody-drug conjugate
US11624093B2 (en) 2014-04-24 2023-04-11 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
BR112016024363A2 (en) 2014-04-25 2017-10-10 Pf Medicament antibody-drug conjugate and its use for cancer treatment
CN106459204B (en) 2014-04-25 2021-02-02 皮埃尔法布雷医药公司 IGF-1R antibodies and their use as localization vectors for the treatment of cancer
HUE044862T2 (en) 2014-04-25 2019-11-28 Pf Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
AP2016009504A0 (en) 2014-04-27 2016-10-31 Ccam Biotherapeutics Ltd Humanized antibodies against ceacam1
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
TWI713453B (en) 2014-06-23 2020-12-21 美商健生生物科技公司 Interferon alpha and omega antibody antagonists
US10273311B2 (en) 2014-06-26 2019-04-30 Yale University Compositions to regulate renalase in the treatment of diseases and disorders
ES2825708T3 (en) 2014-07-17 2021-05-17 Univ Pennsylvania Methods for using exosomes to monitor transplanted organ status
CN112979828A (en) 2014-07-17 2021-06-18 恺兴生命科技(上海)有限公司 T lymphocyte targeting CLD18A2 and preparation method and application thereof
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
MY180054A (en) 2014-09-30 2020-11-20 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
SG10201902924RA (en) 2014-10-03 2019-05-30 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
US20170319661A1 (en) 2014-12-03 2017-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
CA2977532A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
JP2018516230A (en) 2015-03-18 2018-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティ Novel monoclonal antibody inhibitor targeting potassium channel KCNK9
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
EP3277309A1 (en) 2015-04-03 2018-02-07 Alienor Farma Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
EP3283108B1 (en) 2015-04-13 2020-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
WO2016170027A1 (en) 2015-04-22 2016-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
WO2016193301A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
EA201792661A1 (en) 2015-06-01 2018-05-31 Медиджин Иммьюнотерапиз Гмбх METHOD OF OBTAINING ANTIBODIES AGAINST T-CELL RECEPTOR
CA2987857A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T cell receptor library
CN107922457B (en) 2015-06-19 2022-05-13 森托瑞恩生物制药公司 Delivery system for controlled drug release
JP2018524588A (en) 2015-06-26 2018-08-30 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド Cancer therapy targeting tetraspanin 33 (Tspan33) in bone marrow-derived suppressor cells
JP6787890B2 (en) 2015-06-29 2020-11-18 第一三共株式会社 Method for selective production of antibody-drug conjugate
EP3331563B1 (en) 2015-08-05 2023-04-19 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
WO2017046335A1 (en) 2015-09-18 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
ES2940360T3 (en) 2015-09-22 2023-05-05 Inst Nat Sante Rech Med Polypeptides capable of inhibiting the binding between leptin and neuropilin-1
EP3660051A1 (en) 2015-09-24 2020-06-03 Daiichi Sankyo Company, Limited Anti-garp antibody
BR112018006360A2 (en) 2015-09-30 2018-10-09 Janssen Biotech Inc agonistic antibodies that specifically bind to human cd40 and methods of use
JP6857360B2 (en) 2015-10-08 2021-04-14 国立大学法人東海国立大学機構 Method for preparing gene-modified T cells expressing chimeric antigen receptor
EP3362093A4 (en) 2015-10-13 2019-05-08 Technion Research & Development Foundation Limited Heparanase-neutralizing monoclonal antibodies
WO2017064302A1 (en) 2015-10-16 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
WO2017072196A1 (en) 2015-10-26 2017-05-04 Pierre Fabre Medicament Composition for the treatment of igf-1r expressing cancer
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
ITUB20155272A1 (en) 2015-11-02 2017-05-02 Scuola Normale Superiore Intracellular antibody
CN108473584B (en) 2015-11-03 2022-01-14 詹森生物科技公司 Antibodies that specifically bind to PD-1 and TIM-3 and uses thereof
JP2019503985A (en) 2015-11-03 2019-02-14 グリコミメティクス， インコーポレイテッド Monoclonal antibodies, methods and compositions for the production of hematopoietic stem cells, and methods of using them
ITUB20155097A1 (en) 2015-11-05 2017-05-05 Biouniversa Srl Humanized anti-BAG3 antibodies
EP3386542B1 (en) 2015-12-10 2020-11-18 Katholieke Universiteit Leuven Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
EP3390453A2 (en) 2015-12-17 2018-10-24 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
HUE053674T2 (en) 2015-12-23 2021-07-28 Medigene Immunotherapies Gmbh Novel generation of antigen-specific tcrs
EP3397966B1 (en) 2015-12-31 2021-09-29 Progastrine et Cancers S.à r.l. Compositions and methods for detecting and treating gastric cancer
CA3009785A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.A R.L. Compositions and methods for detecting and treating esophageal cancer
CN108780091A (en) 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 Composition for detecting and treating oophoroma and method
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
EP3205663A1 (en) 2016-02-15 2017-08-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for inhibiting gene expression
EP3416688B1 (en) 2016-02-15 2022-08-17 INSERM - Institut National de la Santé et de la Recherche Médicale Apelin for use in the treatment of post-operative cognitive dysfunction
BR112018067522A2 (en) 2016-03-01 2019-02-05 Univ Of Rijeka Faculty Of Medicine human poliovirus receptor (pvr) specific antibodies
US11340233B2 (en) 2016-03-07 2022-05-24 Pierre Fabre Medicament Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
WO2017156263A1 (en) 2016-03-09 2017-09-14 Memorial Sloan-Kettering Cancer Center Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
HRP20220335T1 (en) 2016-03-15 2022-05-13 Institut National De La Santé Et De La Recherche Médicale (Inserm) Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
RU2744959C2 (en) 2016-03-23 2021-03-17 Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд New anti-pd-l1 antibodies
SI3436461T1 (en) 2016-03-28 2024-03-29 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
ITUA20162242A1 (en) 2016-04-01 2017-10-01 St Biochimico Italiano Giovanni Lorenzini Spa A NEW ANTI-ERBB2 ANTIBODY
EP4124362A1 (en) 2016-04-18 2023-02-01 Faron Pharmaceuticals OY Methods of monitoring a modulation of m2 macrophages into m1 macrophages
US11406686B2 (en) 2016-05-03 2022-08-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of tissue lesions with CCR2 agonists
CN115873904A (en) 2016-05-11 2023-03-31 美国安进公司 Direct selection of cells expressing high levels of heteromeric proteins using complementary vectors in the glutamine synthetase gene
US20190290756A1 (en) 2016-05-20 2019-09-26 Christoph Karl Pharmaceutical compositions with anti-rankl antibodies, calcium and vitamin d
EP3464357A1 (en) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
WO2017202814A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
AU2017276706A1 (en) 2016-06-07 2019-01-03 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
AU2017292172A1 (en) 2016-07-06 2019-01-03 Prothena Biosciences Limited Assay for detecting total and S129 phosphorylated alpha-synuclein
JP2018035137A (en) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ Novel anti-fibroblast activated protein (FAP) binding agent and use thereof
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
JP2019528437A (en) 2016-07-28 2019-10-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Method for treating cancer diseases by targeting tumor-associated macrophages
MA45941A (en) 2016-08-12 2019-06-19 Janssen Biotech Inc FC-MODIFIED ANTI-TNFR SUPERFAMILY ANTIBODIES WITH IMPROVED AGONIST ACTIVITY AND THEIR USE PROCEDURES
US10669344B2 (en) 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
US11136409B2 (en) 2016-09-20 2021-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
CN109789211A (en) 2016-10-07 2019-05-21 第一三共株式会社 Treatment based on the patience cancer that Anti-HER 2-drug conjugates are bestowed
EP3527225A4 (en) 2016-10-12 2020-06-10 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
IT201600111877A1 (en) 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
RU2767793C2 (en) 2016-11-18 2022-03-21 Астеллас Фарма Инк. Novel fab fragment of anti-human muc1 antibody
WO2018110515A1 (en) 2016-12-12 2018-06-21 第一三共株式会社 Combination of antibody-drug conjugate and immune checkpoint inhibitor
US11180554B2 (en) 2016-12-13 2021-11-23 Astellas Pharma Inc. Anti-human CD73 antibody
KR20190091483A (en) 2016-12-15 2019-08-06 더 내셔널 인스티튜트 포 바이오테크놀로지 인 더 네게브 엘티디. Anti-PCNA Monoclonal Antibodies and Uses thereof
MX2019007347A (en) 2016-12-22 2019-12-05 Daiichi Sankyo Co Ltd Anti-cd3 antibody, and molecule containing said antibody.
US20180179490A1 (en) 2016-12-27 2018-06-28 Miltenyi Biotec Gmbh CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
AU2018210081A1 (en) 2017-01-17 2019-08-08 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
SG11201907321TA (en) 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
EP3363459A1 (en) 2017-02-17 2018-08-22 Alexander Klimka Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
WO2018157169A1 (en) 2017-02-27 2018-08-30 Caerus Therapeutics, Inc. Antibody constructs and methods of treating cancer
CN110475569B (en) 2017-02-28 2023-11-21 第一三共株式会社 EGFR-TKI-resistant non-small cell lung cancer therapeutic agent and application of anti-HER 3 antibody-drug conjugate
EP3596126A4 (en) 2017-03-15 2021-03-03 Tsinghua University Novel anti-trkb antibodies
JOP20180021A1 (en) 2017-03-16 2019-01-30 Janssen Biotech Inc Anti-phf-tau antibodies and uses thereof
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
TWI782000B (en) 2017-03-30 2022-11-01 日商第一三共股份有限公司 Anti gpr20 antibodies, preparation method and application thereof
CN110678753B (en) 2017-03-30 2023-10-24 普莱戈斯瑞恩癌症有限责任公司 Compositions and methods for treating lung cancer
CN110945025B (en) 2017-03-30 2023-11-03 Ecs前胃泌素股份有限公司 Compositions and methods for detecting prostate cancer
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
US20190016810A1 (en) 2017-05-11 2019-01-17 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents
TW202330036A (en) 2017-05-15 2023-08-01 日商第一三共股份有限公司 Manufacturing method of antibody-drug conjugates
CR20190550A (en) 2017-06-05 2020-04-05 Janssen Biotech Inc Antibodies that specifically bind pd-1 and methods of use
WO2018226685A2 (en) 2017-06-06 2018-12-13 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
WO2019005503A1 (en) 2017-06-29 2019-01-03 Rutgers, The State University Of New Jersey Compositions and methods targeting g12 signaling for bronchodilator therapy
WO2019004487A1 (en) 2017-06-30 2019-01-03 国立大学法人北海道大学 Pediatric osteoporosis drug that does not cause growth disorder
TWI795415B (en) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 A novel anti-human CEACAM5 antibody Fab fragment
US11464845B2 (en) 2017-07-21 2022-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neisseria meningitidis immunogenic compositions
BR112020001657A2 (en) 2017-07-27 2020-07-21 Daiichi Sankyo Company, Limited ANTIBODY AGAINST HUMAN CD147, ANTIBODY ANTIGEN BINDING FRAGMENT, PHARMACEUTICAL COMPOSITION, ANTIBODY OR ANTIGEN BINDING FRAGMENT, POLYNUCLEOTIDE ANTIBODY, EXPRESSION VECTOR, HOSEPHORUS CELL , TO PROGNOSTIC RESPONSIVITY TO CANCER TREATMENT AND TO SELECT SUBJECTS FOR CANCER TREATMENT, KIT TO DETERMINE RESPONSIVENESS TO CANCER TREATMENT, ANTIBODY AND ANTIBODY COMPOUND BODY,
CA3107625A1 (en) 2017-07-28 2019-01-31 Biouniversa S.R.L. Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases
CN117050176A (en) 2017-07-31 2023-11-14 豪夫迈·罗氏有限公司 Humanization method based on three-dimensional structure
EP3444272A1 (en) 2017-08-17 2019-02-20 International-Drug-Development-Biotech Treatment of ck8 positive cancers in relation with k-ras gene status
US11643468B2 (en) 2017-08-23 2023-05-09 Max-Delbrück-Centrum für Molekulare Medizin in der Hemlholtz-Gemeinschaft Chimeric antigen receptors and CAR-T cells that bind CXCR5 and methods of use thereof to treat medical disorders
TW201919710A (en) 2017-08-23 2019-06-01 日商第一三共股份有限公司 Formulation of antibody-drug conjugate and lyophilization method thereof
CN117865839A (en) 2017-08-31 2024-04-12 第一三共株式会社 New method for preparing antibody-drug conjugate
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
BR112020004126A2 (en) 2017-09-29 2020-09-08 Daiichi Sankyo Company, Limited antibody-derived pyrrolbenzodiazepine conjugate
CN111065400A (en) 2017-10-03 2020-04-24 公益财团法人东京都医学总合研究所 Anti-influenza medicine
EP3693012A4 (en) 2017-10-05 2021-07-21 Daiichi Sankyo Company, Limited Composition for cytotoxic t cell depletion
KR101966362B1 (en) * 2017-10-20 2019-04-05 주식회사 녹십자 Antibody against msln and pharmaceutical composition for treating cancer comprising the same
JP2021502125A (en) 2017-11-09 2021-01-28 ピンテオン セラピューティクス インコーポレイテッド Methods and Compositions for the Preparation and Use of Humanized Conformation-Specific Phosphorylated Tau Antibodies
JP7359449B2 (en) 2017-11-30 2023-10-11 センチュリオン バイオファーマ コーポレイション Albumin-binding prodrug of auristatin E derivative
WO2019108975A1 (en) 2017-11-30 2019-06-06 Centurion Biopharma Corporation Maytansinoid-based drug delivery systems
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
CA3084687C (en) 2017-12-05 2024-01-02 Progastrine Et Cancers S.A R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
US20190225689A1 (en) 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
TW201940881A (en) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 Combining progastrin detection with other cancer biomarkers in cancer diagnosis
US11834487B2 (en) 2018-02-12 2023-12-05 Hadasit Medical Research Services & Development Ltd. Modulation of SLAMF6 splice variants for cancer therapy
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
MA52422A (en) 2018-02-27 2021-01-06 Incyte Corp IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
CA3092414A1 (en) 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
BR112020017451A2 (en) 2018-03-05 2020-12-22 Saitama Medical University PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF HETEROTOPIC OSSIFICATION
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
EP3775908A1 (en) 2018-04-13 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
SG11202009626QA (en) 2018-04-20 2020-10-29 Medizinische Hochschule Hannover Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
WO2019207066A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of sjögren's syndrome
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
KR20210009308A (en) 2018-05-09 2021-01-26 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Antibodies specific to human Nectin 4
AU2019268022A1 (en) 2018-05-11 2020-11-26 Astellas Pharma Inc. Nucleic acid for treating mite allergy
US20210163549A1 (en) 2018-05-11 2021-06-03 Astellas Pharma Inc. Nucleic acid for treating crustacean allergy
WO2019221269A1 (en) 2018-05-17 2019-11-21 アステラス製薬株式会社 COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY Fab FRAGMENT, PEPTIDE LINKER AND/OR LIGAND
MA52940A (en) 2018-05-18 2021-04-28 Incyte Corp FUSION PYRIMIDINE DERIVATIVES USED AS A2A / A2B INHIBITORS
AU2019274652A1 (en) 2018-05-24 2020-11-26 Janssen Biotech, Inc. Monospecific and multispecific anti-TMEFF2 antibodies and there uses
MX2020012587A (en) 2018-05-24 2021-04-28 Janssen Biotech Inc Anti-cd3 antibodies and uses thereof.
BR112020023872A2 (en) 2018-05-24 2021-02-17 Janssen Biotech, Inc. psma binding agents and their uses
CA3101906A1 (en) 2018-05-28 2019-12-05 Daiichi Sankyo Company, Limited Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
AR126019A1 (en) 2018-05-30 2023-09-06 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
AU2019279206A1 (en) 2018-05-31 2020-12-03 Daiichi Sankyo Company, Limited Anti-human TLR7 antibody
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
MX2020014158A (en) 2018-06-20 2021-04-12 Incyte Corp Anti-pd-1 antibodies and uses thereof.
TW202016144A (en) 2018-06-21 2020-05-01 日商第一三共股份有限公司 Compositions including cd3 antigen binding fragments and uses thereof
AR117600A1 (en) 2018-06-29 2021-08-18 Incyte Corp FORMULATIONS OF AN AXL / MER INHIBITOR
WO2020007898A1 (en) 2018-07-04 2020-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating brain injury or neurodegenerative disease
KR20210038904A (en) 2018-07-25 2021-04-08 다이이찌 산쿄 가부시키가이샤 Effective method for preparing antibody-drug conjugates
US20210308170A1 (en) 2018-07-27 2021-10-07 Osaka University Composition for suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan
TW202019973A (en) 2018-07-27 2020-06-01 日商第一三共股份有限公司 Protein recognizing drug part of antibody-drug conjugate
JPWO2020027100A1 (en) 2018-07-31 2021-08-02 第一三共株式会社 Treatment of metastatic brain tumors with antibody-drug conjugates
CA3108754A1 (en) 2018-08-06 2020-02-13 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor
KR20230122685A (en) 2018-09-06 2023-08-22 다이이찌 산쿄 가부시키가이샤 Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
WO2020059772A1 (en) 2018-09-20 2020-03-26 第一三共株式会社 Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
JPWO2020059847A1 (en) 2018-09-21 2021-09-16 国立大学法人 東京医科歯科大学 A human monoclonal antibody that specifically binds to human HMGB1 and a pharmaceutical composition containing the same for treating or preventing Alzheimer's disease.
EP3856258A1 (en) 2018-09-27 2021-08-04 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
MX2021003580A (en) 2018-09-28 2021-10-13 Pf Medicament New immunocytokines for the treatment of cancer.
MX2021004146A (en) 2018-10-10 2021-06-08 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex.
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
EP3867269A1 (en) 2018-10-18 2021-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
JP7415939B2 (en) 2018-10-31 2024-01-17 アステラス製薬株式会社 Anti-human Fn14 antibody
EP3880706A1 (en) 2018-11-12 2021-09-22 MediaPharma S.r.l. Bispecific antibodies directed against human 90k and either endosialin or her3
SG11202104993SA (en) 2018-11-14 2021-06-29 Daiichi Sankyo Co Ltd Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
CA3122946A1 (en) 2018-12-11 2020-06-18 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with parp inhibitor
CN113195000A (en) 2018-12-21 2021-07-30 第一三共株式会社 Combination of antibody-drug conjugates and kinase inhibitors
AU2019403445A1 (en) 2018-12-21 2021-07-29 Aim Immunotech Inc. Compositions and methods for cancer therapy
KR20210113201A (en) 2019-01-07 2021-09-15 아스텔라스세이야쿠 가부시키가이샤 Complex comprising a ligand and a CEACAM5 antibody Fab fragment
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
WO2020144697A1 (en) 2019-01-13 2020-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human nectin-2
WO2020157122A1 (en) 2019-01-29 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
MX2021009662A (en) 2019-02-13 2021-09-08 Brigham & Womens Hospital Inc Anti-peripheral lymph node addressin antibodies and uses thereof.
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
WO2020193441A1 (en) 2019-03-22 2020-10-01 Université de Paris New inhibitors of lrrk2/pp1 interaction
TW202102225A (en) 2019-03-25 2021-01-16 日商第一三共股份有限公司 Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate
CA3130872A1 (en) 2019-03-25 2020-10-01 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Enhancement of cytolytic t-cell activity by inhibiting ebag9
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CN113631191A (en) 2019-03-27 2021-11-09 第一三共株式会社 Combination of antibody-pyrrolobenzodiazepine derivative conjugates with PARP inhibitors
WO2020204033A1 (en) 2019-04-01 2020-10-08 株式会社カイオム・バイオサイエンス Medicament for treating cancer
WO2020206033A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CA3136888A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
EP3969569A1 (en) 2019-05-14 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
KR20220015445A (en) 2019-05-29 2022-02-08 다이이찌 산쿄 가부시키가이샤 Administration of Antibody-Drug Conjugates
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
US20220267453A1 (en) 2019-07-26 2022-08-25 Saitama Medical University Antibody recognizing extracellular region of alk2/acvr1
CR20220025A (en) 2019-07-26 2022-05-04 Janssen Biotech Inc Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2021019706A1 (en) 2019-07-31 2021-02-04 国立大学法人信州大学 Method for producing cell mass containing car-expressing immunocytes
US20210030869A1 (en) 2019-08-01 2021-02-04 Incyte Corporation Dosing regimen for an ido inhibitor
CA3146474A1 (en) 2019-08-02 2021-02-11 Denis BURGER Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
EP4013510A1 (en) 2019-08-12 2022-06-22 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
EP3792632A1 (en) 2019-09-16 2021-03-17 Vito NV Immunotherapy markers
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
WO2021059075A1 (en) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
US20220290151A1 (en) 2019-09-27 2022-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of müllerian inhibiting substance inhibitors for treating cancer
EP4049675A4 (en) 2019-10-25 2023-11-22 Daiichi Sankyo Company, Limited Combination of anti-garp antibody and immunoregulator
AU2020381534A1 (en) 2019-11-15 2022-06-23 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
EP4073123A4 (en) * 2019-12-10 2024-01-10 Ccoa Therapeutics Inc Humanized anti-glycoprotein ib alpha (gpibalpha) antibodies
CA3164996A1 (en) 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
CA3166549A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
US20230070181A1 (en) 2020-02-05 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of cancer disease by targeting an epigenetic factor
TW202140012A (en) 2020-02-12 2021-11-01 比利時商健生藥品公司 Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
TW202144388A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in ovarian cancer and their uses
TW202144389A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in multiple myeloma and their uses
US20230085883A1 (en) 2020-03-03 2023-03-23 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
IL296065A (en) 2020-03-06 2022-10-01 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
MX2022009597A (en) 2020-03-06 2022-09-02 Daiichi Sankyo Co Ltd Antibody-drug conjugate including novel cyclic dinucleotide derivative.
AU2021232853A1 (en) 2020-03-10 2022-09-22 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
EP4117715A1 (en) 2020-03-13 2023-01-18 Janssen Biotech, Inc. Materials and methods for binding siglec-3/cd33
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
JPWO2021200131A1 (en) 2020-03-30 2021-10-07
EP3889183A1 (en) 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
KR20220164787A (en) 2020-04-06 2022-12-13 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Antibodies to NKp46 and constructs thereof for the treatment of cancer and infections
EP4151655A1 (en) 2020-05-14 2023-03-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
JP2023526529A (en) 2020-05-19 2023-06-21 アンスティテュ・クリー Methods of Diagnosis and Treatment of Cytokine Release Syndrome
AU2021281828A1 (en) 2020-05-27 2023-02-02 Arialys Therapeutics, Inc. Anti-human NR1 antibody derivative
CA3184189A1 (en) 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
AU2021283080A1 (en) 2020-06-04 2022-12-15 Kenjockety Biotechnology, Inc. ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
IL299368A (en) 2020-06-24 2023-02-01 Astrazeneca Uk Ltd Combination of antibody-drug conjugate and atr inhibitor
EP4171654A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and cdk9 inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
WO2021260139A1 (en) 2020-06-25 2021-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment and diagnostic of pathological conditions associated with intense stress
EP4183799A1 (en) 2020-07-17 2023-05-24 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
KR20230042055A (en) 2020-07-20 2023-03-27 다이이찌 산쿄 가부시키가이샤 Combinations of anti-HER2 antibody-drug conjugates with HER dimerization inhibitors
CA3190307A1 (en) 2020-07-29 2022-02-03 Janssen Biotech, Inc. Proteins comprising hla-g antigen binding domains and their uses
RU2764216C1 (en) * 2020-08-10 2022-01-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Method for treating glomerulonephrites with nephrotic syndrome with a relapsing course
MX2023001776A (en) 2020-08-12 2023-03-10 Biond Biologics Ltd Antibodies against ilt2 and use thereof.
US20230321242A1 (en) 2020-08-24 2023-10-12 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (car)-expressing cells recognizing cea
US20240009310A1 (en) 2020-08-24 2024-01-11 Charité - Universitätsmedizin Berlin A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
WO2022051591A2 (en) 2020-09-04 2022-03-10 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
WO2022049273A1 (en) 2020-09-07 2022-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of inflammatory bowel diseases
EP4211598A2 (en) 2020-09-12 2023-07-19 AstraZeneca UK Limited A scoring method for an anti-her2 antibody-drug conjugate therapy
JPWO2022075482A1 (en) 2020-10-05 2022-04-14
CA3195117A1 (en) 2020-10-09 2022-04-14 Jerome Thomas Mettetal Ii Combination of antibody-drug conjugate and parp1 selective inhibitor
TW202231292A (en) 2020-10-13 2022-08-16 美商健生生物科技公司 Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv and/or viii
US20230416346A1 (en) 2020-10-21 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) C-terminal sparc fragments for treating cancer
CA3199319A1 (en) 2020-10-22 2022-04-28 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
WO2022097090A1 (en) 2020-11-05 2022-05-12 Novartis Ag Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
KR20230113564A (en) 2020-11-06 2023-07-31 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Methods for Diagnosing and Treating Polycystic Ovarian Syndrome (PCOS)
AU2021378152A1 (en) 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
JPWO2022102695A1 (en) 2020-11-12 2022-05-19
CN116635071A (en) 2020-11-16 2023-08-22 安斯泰来制药株式会社 anti-TSPAN 8-anti-CD 3 bispecific antibodies and anti-TSPAN 8 antibodies
US20240003879A1 (en) 2020-11-27 2024-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring of toxic epidermal necrolysis
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
JP2023551519A (en) 2020-11-30 2023-12-08 インサイト・コーポレイション Combination therapy of anti-CD19 antibody and parsaclisib
US20240025985A1 (en) 2020-12-09 2024-01-25 National University Corporation Tokyo Medical And Dental University Agent for Preventing or Treating Frontotemporal Lobar Degeneration
TW202241441A (en) 2020-12-29 2022-11-01 美商英塞特公司 Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
KR20230146522A (en) 2021-01-13 2023-10-19 메모리얼 슬로안 케터링 캔서 센터 Anti-DLL3 antibody-drug conjugate
JP2024503657A (en) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター Antibody-pyrrolobenzodiazepine derivative conjugate
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
WO2022162518A2 (en) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
TW202241454A (en) 2021-02-01 2022-11-01 日商第一三共股份有限公司 Novel method for producing antibody-immunostimulator conjugate
CN116829591A (en) 2021-02-11 2023-09-29 奈克汀治疗有限公司 Antibodies against CD112R and uses thereof
WO2022171771A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
IL305575A (en) 2021-03-02 2023-10-01 Dana Farber Cancer Inst Inc Methods of treating red blood cell disorders
EP4306546A1 (en) 2021-03-12 2024-01-17 Daiichi Sankyo Company, Limited Glycan, and method for producing medicine containing glycan
EP4305064A1 (en) 2021-03-12 2024-01-17 Fibrosys S.r.l. Monoclonal antibodies for the treatment of viral infections
IL306103A (en) 2021-03-24 2023-11-01 Janssen Biotech Inc Antibody targeting cd22 and cd79b
KR20230162793A (en) 2021-03-26 2023-11-28 얀센 바이오테크 인코포레이티드 Humanized antibodies against paired helical filament tau and uses thereof
WO2022218998A1 (en) 2021-04-13 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating hepatitis b and d virus infection
IL307267A (en) 2021-04-14 2023-11-01 Villaris Therapeutics Inc Anti-cd122 antibodies and uses thereof
AU2022262542A1 (en) 2021-04-22 2023-11-02 Astellas Pharma Inc. Anti-cldn4/anti-cd137 bispecific antibody
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CN113361141B (en) * 2021-07-11 2022-02-18 西南石油大学 Improved test method of DNA map algorithm
TW202320861A (en) 2021-09-15 2023-06-01 日商第一三共股份有限公司 Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
WO2023073084A1 (en) 2021-10-27 2023-05-04 Imcheck Therapeutics Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
EP4177266A1 (en) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
WO2023089527A1 (en) 2021-11-18 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
TW202334231A (en) 2021-12-22 2023-09-01 德商莫菲西斯公司 Treatment paradigm for an anti-cd19 antibody therapy
WO2023126822A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
TW202339805A (en) 2021-12-28 2023-10-16 英商阿斯特捷利康英國股份有限公司 Combination of antibody-drug conjugate and atr inhibitor
WO2023152581A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
WO2023166081A1 (en) 2022-03-02 2023-09-07 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
WO2023175483A1 (en) 2022-03-16 2023-09-21 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody‑drug conjugate therapy
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023218378A1 (en) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2024013724A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody-drug conjugates
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
US20240101718A1 (en) 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JPS6033453B2 (en) * 1978-08-17 1985-08-02 富士電機株式会社 Fish cutting processing automation equipment
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6014678A (en) * 1983-07-04 1985-01-25 Taiheiyo Kogyo Kk Solenoid valve
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
DK554986A (en) * 1986-11-19 1988-07-18 Novo Industri As HUMAN-HUMAN HYBRID CELL LINES AND MANUFACTURED MONOCLONAL CANCER ANTIBODIES
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
AU631545B2 (en) * 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
JP5598363B2 (en) 2011-02-15 2014-10-01 ソニー株式会社 Storage device and operation method thereof

Also Published As

Publication number Publication date
JP2007145863A (en) 2007-06-14
ATE183753T1 (en) 1999-09-15
DE10075038I2 (en) 2004-08-12
EP1491556B1 (en) 2014-04-30
JP2828340B2 (en) 1998-11-25
DE04076438T1 (en) 2014-02-27
AU5153290A (en) 1990-08-13
NO2005005I2 (en) 2009-01-19
DE122009000071I1 (en) 2010-03-25
NL300213I1 (en) 2006-02-01
NO2001024I1 (en) 2002-01-21
WO1990007861A1 (en) 1990-07-26
EP0682040B1 (en) 1999-08-25
KR0178385B1 (en) 1999-04-01
DK174317B1 (en) 2002-12-02
LU91627I2 (en) 2010-02-09
DE122005000057I2 (en) 2009-07-16
NO2001025I2 (en) 2005-03-21
CN1043875A (en) 1990-07-18
DE10075038I1 (en) 2001-03-01
DK199800941A (en) 1998-07-16
LU90411I2 (en) 1999-09-02
EP0939127A2 (en) 1999-09-01
LU91272I2 (en) 2006-10-09
NL300005I2 (en) 2000-10-02
NO2006009I2 (en) 2009-12-07
IE20000331A1 (en) 2001-02-21
EP0939127B1 (en) 2014-09-17
MC2146A1 (en) 1992-02-18
DE122005000007I1 (en) 2005-06-30
CA2006865A1 (en) 1990-06-28
CA2006865C (en) 2002-08-20
ES2440825T1 (en) 2014-01-30
JPH114694A (en) 1999-01-12
NZ314793A (en) 1999-11-29
NL300173I2 (en) 2006-05-01
EP0682040A1 (en) 1995-11-15
NL300279I2 (en) 2007-10-01
NO2005026I2 (en) 2009-01-19
EP0939127A3 (en) 2004-07-21
ES2492815T3 (en) 2014-10-08
NL300239I1 (en) 2006-10-02
CN1057013C (en) 2000-10-04
SG78258A1 (en) 2001-02-20
NZ231984A (en) 1997-06-24
FI912436A0 (en) 1991-05-20
CZ418691A3 (en) 1993-10-13
DE68925536T4 (en) 1996-09-19
HRP920500B1 (en) 1999-12-31
DE68925536T3 (en) 2012-11-22
EP0451216A1 (en) 1991-10-16
CA2328851A1 (en) 1990-06-28
DE04076439T1 (en) 2014-12-18
JP2009165488A (en) 2009-07-30
LU91208I2 (en) 2006-02-28
JP2003245090A (en) 2003-09-02
NL300426I1 (en) 2010-02-01
LU91333I2 (en) 2007-06-11
DE68929061T2 (en) 2000-04-27
NL300239I2 (en) 2007-03-01
RU2126046C1 (en) 1999-02-10
DE10075005I2 (en) 2005-06-23
DE122005000007I2 (en) 2009-06-25
NL300005I1 (en) 2000-04-03
DE19975047I2 (en) 2008-07-03
EP0451216B9 (en) 2012-09-26
ES2523810T3 (en) 2015-01-12
NO2006009I1 (en) 2006-08-07
NL300023I2 (en) 2001-09-03
NO2007006I1 (en) 2007-05-07
NO912385L (en) 1991-06-19
HRP920500A2 (en) 1996-04-30
NL990020I2 (en) 1999-11-01
PT92758B (en) 1996-01-31
DE98204240T1 (en) 2014-08-21
DE68925536D1 (en) 1996-03-07
EP0451216B2 (en) 2012-06-13
JP2003245091A (en) 2003-09-02
HU211174A9 (en) 1995-11-28
ZA899956B (en) 1990-10-31
DE122007000037I1 (en) 2007-08-02
EP1477497A1 (en) 2004-11-17
BG61095B2 (en) 1996-10-31
SI8912489A (en) 1999-02-28
IL162181A0 (en) 2005-11-20
DE10075005I1 (en) 2000-11-23
YU248989A (en) 1991-10-31
LU90676I2 (en) 2001-02-05
EP0451216B1 (en) 1996-01-24
JPH04502408A (en) 1992-05-07
ES2081974T5 (en) 2012-10-29
FR14C0070I1 (en) 2014-10-24
NO2005026I1 (en) 2005-12-27
ES2492815T1 (en) 2014-09-10
ES2136760T3 (en) 1999-12-01
NL300023I1 (en) 2001-01-02
SI8912489B (en) 2000-04-30
JP3604058B2 (en) 2004-12-22
NO2009026I1 (en) 2009-11-30
DE68929061D1 (en) 1999-09-30
EP1477497B1 (en) 2014-11-26
HK1014718A1 (en) 1999-09-30
IL92904A0 (en) 1990-09-17
DK119191A (en) 1991-06-19
EP2341080A1 (en) 2011-07-06
KR910700350A (en) 1991-03-14
NL300279I1 (en) 2007-07-02
IL162181A (en) 2006-04-10
DE122005000057I1 (en) 2009-04-09
ES2081974T3 (en) 1996-03-16
NO2001026I2 (en) 2006-11-20
DD296964A5 (en) 1991-12-19
ES2440825T3 (en) 2014-05-19
EP1491556A1 (en) 2004-12-29
ES2523810T1 (en) 2014-12-01
DK119191D0 (en) 1991-06-19
FI108797B (en) 2002-03-28
AU647383B2 (en) 1994-03-24
EP0451216A4 (en) 1992-01-02
LU91139I2 (en) 2005-04-04
NL300213I2 (en) 2006-07-03
LU90528I2 (en) 2000-04-11
CA2328851C (en) 2002-08-13
NO2007006I2 (en) 2009-12-07
ATE133452T1 (en) 1996-02-15
DE68925536T2 (en) 1996-06-20
NO310473B1 (en) 2001-07-09
NL300173I1 (en) 2005-04-01
NL990020I1 (en) 1999-09-01
NO912385D0 (en) 1991-06-19
PT92758A (en) 1990-06-29
YU48700B (en) 1999-07-28

Similar Documents

Publication Publication Date Title
DE122007000037I1 (en) Humanized immunoglobulins, their preparation and use